Results 181 to 190 of about 76,403 (315)

The Intersection of Lynch Syndrome and Hematological Malignancies: A Rare Short Report. [PDF]

EJHaem
Oka T, Nakajima T, Iwasaki M, Takeda J, Torishima M, Sakurada M, Shimizu T, Shindo T, Fujimoto M, Otsuki S, Haga H, Sugano K, Ando M, Mizumoto C, Kanda J, Nannya Y, Ogawa S, Takaori-Kondo A, Kosugi S.   +18 more
europepmc   +1 more source

Significance of parathyroid hormone-related protein as a factor stimulating bone resorption and causing hypercalcemia in myeloma [PDF]

, 1998
Hideki Tsujimura, Fumitaka Nagamura, Tohru Iseki, Shoichiro Kanazawa, Hiromitsu Saisho   +4 more
openalex   +1 more source

Plasmonic Mesoporous Gold‐Based SERS Biosensor for Ovarian Cancer‐Derived Extracellular Vesicles

Small, EarlyView.
The nanoengineered mesoporous gold (mAu)‐based SERS platform enables rapid, sensitive detection of PLAP‐positive extracellular vesicles (EVs) in ovarian cancer (OC), with detection limits as low as 100 EVs mL−1. Achieving over 80% sensitivity and 98% specificity in clinical samples, this cost‐effective, non‐invasive tool shows promise for early cancer ...
Javeria Bashir, Mostafa Kamal Masud, Asep Sugih Nugraha, Chia‐Hung Liu, Arya Vasanth, Aditya Ashok, S M Azad Hossain, Emtiaz Ahmed, Tanja Pejovic, Terry Morgan, John Hooper, Andrew Lai, Dominic Guanzon, Yusuf Valentino Kaneti, Md Shahriar A. Hossain, Carlos Salomon, Yusuke Yamauchi   +16 more
wiley   +1 more source

Targeting myeloma metabolism: How abnormal metabolism contributes to multiple myeloma progression and resistance to proteasome inhibitors

Neoplasia: An International Journal for Oncology Research
Multiple myeloma is a hematological malignancy that has evolved from antibody-secreting B lymphocytes. Like other types of cancers, myeloma cells have acquired functional capabilities which are referred to as “Hallmarks of Cancer”, and one of their most ...
Xiang Zhou, Rui He, Wei-Xin Hu, Saiqun Luo, Jingping Hu   +4 more
doaj  

Impact of proteostasis workload on sensitivity to proteasome inhibitors in multiple myeloma. [PDF]

Clin Exp Med
Sedlacek J.
europepmc   +1 more source

Idiotypic protein‐pulsed dendritic cell vaccination in multiple myeloma [PDF]

, 1999
Seah H. Lim, R Bailey-Wood
openalex   +1 more source

Targeted Delivery of miR‐34a via Anti‐CD47 Antibody Conjugates for Enhanced Cancer Immunotherapy in Triple Negative Breast Cancer

Small, EarlyView.
aCD47‐C‐miR34a, an antibody‐oligonucleotide platform combining an anti‐CD47 antibody with miR‐34a, is designed for targeted therapy in TNBC. This approach improved delivery and restored the tumor‐suppressing function of miR‐34a, enhanced CD8+ T‐cell activation, and inhibited tumor growth, providing a potential strategy to overcome immune evasion and ...
Youngri Ryu, Eun Hye Kim, Hochung Jang, Yelee Kim, Byeongmin Park, Jiwoong Choi, Yeongji Jang, Sung‐Gil Chi, Man Kyu Shim, Sun Hwa Kim, Hong Yeol Yoon, Yoosoo Yang   +11 more
wiley   +1 more source

Polymorphisms in Necroptosis Pathway Genes: Novel Prognostic Markers for Multiple Myeloma Treatment Outcomes. [PDF]

Int J Mol Sci
Sokołowski M, Łacina P, Bogunia-Kubik K, Mazur G, Butrym A.   +4 more
europepmc   +1 more source

PROTEINS IN MULTIPLE MYELOMA [PDF]

Journal of Biological Chemistry, 1956
Aiko Miyake, Frank W. Putnam, Franz Meyer   +2 more
openaire   +2 more sources

Radiolabeled Nanogels: From Multimodality Imaging to Combination Therapy of Cancer

Small Science, EarlyView.
Nanogel refers to nanosized particles formed by physical or chemical crosslinking of polymers. Rational design and refinement of nanogel properties are imperative to unlock their full potential, ensuring tailored solutions for personalized cancer management. This review elucidates the transformative potential of radiolabeled nanogels in revolutionizing
Sanchita Ghosh, Weibo Cai, Rubel Chakravarty   +2 more
wiley   +1 more source